Viyash Scientific (NSE:VIYASH) EBIT: ₹3,099 Mil (TTM As of Mar. 2026)


NSE:VIYASH Viyash Scientific Ltd NSE:VIYASH
72 GF Score
Price ₹269.30
GF Value ₹171.37
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Viyash Scientific EBIT?

Viyash Scientific NSE:VIYASH -0.72% 72 EBIT is ₹3,099 Mil as of Mar. 2026. GuruFocus rates NSE:VIYASH with a GF Score™ of 72/100 and a GF Value™ of ₹171.37 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Viyash Scientific's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹1,398 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹3,099 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Viyash Scientific's annualized ROC % for the quarter that ended in Mar. 2026 was 7.26%. Viyash Scientific's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 23.36%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Viyash Scientific's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.55%.


Viyash Scientific  (NSE:VIYASH) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Viyash Scientific's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=5120 * ( 1 - 47% )/( (0 + 37353.3)/ 1 )
=2713.6/37353.3
=7.26 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Viyash Scientific's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=5590.4/( ( (0 + max(0, 0)) + (12066.3 + max(11860.2, 0)) )/ 1 )
=5590.4/( ( 0 + 23926.5 )/ 1 )
=5590.4/23926.5
=23.36 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(10452.3 + 8032 + 1342.7) - (6213.3 + 0 + 1753.5)
=11860.2

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Viyash Scientific's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=3099.3/121669.254
=2.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Viyash Scientific EBIT Related Terms


Viyash Scientific EBIT Historical Data

* Premium members only.

The historical data trend for Viyash Scientific's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viyash Scientific EBIT Chart

Viyash Scientific Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 664.39 -1,079.39 -82.23 995.50 4,182.30

Viyash Scientific Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -159.80 396.80 406.70 898.20 1,397.60

NSE:VIYASH vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Viyash Scientific's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viyash Scientific EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Viyash Scientific's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Viyash Scientific's EV-to-EBIT falls into.


NSE:VIYASH
72GF Score
Viyash Scientific Ltd NSE:VIYASH
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viyash Scientific EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹3,099 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹3,099 Mil mean?
Viyash Scientific (NSE:VIYASH) has a EBIT of ₹3,099 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Viyash Scientific.
Is Viyash Scientific's EBIT too high?
Viyash Scientific's current EBIT is ₹3,099 Mil. Overall, Viyash Scientific has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viyash Scientific's EBIT compare to ZTS?
Viyash Scientific's EBIT of ₹3,099 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Viyash Scientific. Viyash Scientific's current EBIT is ₹3,099 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viyash Scientific stock overvalued right now?
Based on GuruFocus' analysis, Viyash Scientific (NSE:VIYASH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹171.37, compared to a current price of ₹269.30 — trading 57.1% above its estimated fair value. The current EBIT is ₹3,099 Mil. Viyash Scientific's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Viyash Scientific (NSE:VIYASH), the current EBIT is ₹3,099 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Viyash Scientific (NSE:VIYASH) Overvalued in 2026?

Based on GuruFocus' analysis, Viyash Scientific stock appears to be overvalued. The current stock price of ₹269.30 is trading 57.1% above its estimated GF Value™ of ₹171.37. GuruFocus considers Viyash Scientific to be Significantly Overvalued.

Key valuation signals for NSE:VIYASH:

  • EBIT: ₹3,099 Mil
  • GF Value™: ₹171.37 vs. price of ₹269.30 (57.1% above fair value)
  • GF Score™: 72/100 with 6 warning signs

No single metric tells the full story. See the NSE:VIYASH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Viyash Scientific Business Description

Other Exchanges 512529:India
Address Road No.6, Kakatiya Hills, 3rd Floor, Srivalli’s Corporate, Plot No. 290, Guttala Begumpet, Jubilee Hills, Madhapur, Survey number 33 34P to 39, Hyderabad, KA, IND, 500033
Viyash Scientific Ltd is a pharmaceutical company with activities spanning formulations, active pharmaceutical ingredients (APIs), and intermediates. It is focused on research and development infrastructure for APIs and formulations. Its product portfolio spans several therapeutic areas, including ARV, cardiovascular, central nervous system, analgesics, antibiotics, antihistamines, diabetes, gastrointestinal, anticoagulants, and oncology.
72GF Score

Get the complete analysis for NSE:VIYASH

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹269.30
Price
₹171.37
GF Value